Sacubitril/Valsartan Improves Cardiac Function in Dialysis Patients

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Heart failure (HF) is a serious complication in chronic kidney disease (CKD) patients, particularly those on dialysis.
• Dialysis patients face a significantly higher risk of cardiac arrest, underscoring the need for improved cardiovascular treatments.
• Sacubitril/valsartan (Sac/Val) shows cardioprotective effects but is not approved for advanced CKD or dialysis patients due to safety concerns.

Purpose of the Study:

• To investigate the cardiac effects and safety of Sacubitril/valsartan (Sac/Val) in hemodialysis (HD) patients with heart failure with reduced ejection fraction (HFrEF).

Main Methods:

• A six-month study involving 12 HD patients with HFrEF.
• Administration of Sac/Val at doses ranging from 100-400 mg/day.
• Assessment of cardiac function using echocardiography (ECHO) and quality of life via the Kansas City KCCQ-12 questionnaire.

Main Results:

• Sac/Val treatment gradually improved ejection fraction (EF) without significant changes in cardiac geometry or hemodynamics.
• Patients reported a significant improvement in quality of life.
• No major adverse events were observed during the study period, indicating good safety.

Conclusions:

• Sacubitril/valsartan (Sac/Val) demonstrates potential as a cardioprotective agent in hemodialysis (HD) and peritoneal dialysis (PD) patients.
• The findings support the safety and efficacy of Sac/Val for improving cardiac function and quality of life in dialysis patients with HFrEF.
• Further comprehensive studies with longer follow-up are warranted to solidify these encouraging results.